ScienceExperimental mesothelioma drug reportedly controlled disease progression in 67% of early-trial patients
ScienceDaily reports that the drug disables PRX3, an antioxidant defense tumors use to survive intense oxidative stress.
TLDR
ScienceDaily reports on an experimental treatment for mesothelioma, an aggressive, asbestos-linked cancer with few effective treatments. The drug kills cancer cells by disabling their PRX3 antioxidant defense, according to the report. In an early clinical trial, it controlled disease progression in 67% of patients; the outlet also describes encouraging survival results.
Combined views
22
1 Source, first seen 7d ago
Experimental mesothelioma drug reportedly controlled disease progression in 67% of early-trial patients
ScienceDaily reports that the drug disables PRX3, an antioxidant defense tumors use to survive intense oxidative stress.
TLDR
ScienceDaily reports on an experimental treatment for mesothelioma, an aggressive, asbestos-linked cancer with few effective treatments. The drug kills cancer cells by disabling their PRX3 antioxidant defense, according to the report. In an early clinical trial, it controlled disease progression in 67% of patients; the outlet also describes encouraging survival results.